Kyntra Bio earnings were $215.7M for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. The latest KYNB earnings report on Sep 30, 2025 announced Q3 2025 earnings of $200.6M, down 2,738.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, KYNB reported annual earnings of -$47.6M, with -83.3% growth.
Kyntra Bio (NASDAQ: KYNB) reported Q3 2025 earnings per share (EPS) of $49.61, up 1,267.29% year over year. Total KYNB earnings for the quarter were $200.64 million. In the same quarter last year, Kyntra Bio's earnings per share (EPS) was -$4.25.
As of the last Kyntra Bio earnings report, Kyntra Bio is currently profitable. Kyntra Bio's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $215.65 million, a 277.07% decrease year over year.
What was KYNB's earnings growth in the past year?
As of Kyntra Bio's earnings date in Q1 2026, Kyntra Bio's earnings has grown year over year. KYNB earnings in the past year totalled $215.65 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.